TY  - JOUR
AU  - Ayala, Rosa
AU  - Rapado, Inmaculada
AU  - Onecha, Esther
AU  - Martinez-Cuadron, David
AU  - Carreño-Tarragona, Gonzalo
AU  - Bergua, Juan Miguel
AU  - Vives, Susana
AU  - Algarra, Jesus Lorenzo
AU  - Tormo, Mar
AU  - Martinez, Pilar
AU  - Serrano, Josefina
AU  - Herrera, Pilar
AU  - Ramos, Fernando
AU  - Salamero, Olga
AU  - Lavilla, Esperanza
AU  - Gil, Cristina
AU  - Lopez-Lorenzo, Jose Luis
AU  - Vidriales, Maria Belen
AU  - Labrador, Jorge
AU  - Falantes, Jose Francisco
AU  - Sayas, Maria Jose
AU  - Paiva, Bruno
AU  - Barragan, Eva
AU  - Prosper, Felipe
AU  - Sanz, Miguel Angel
AU  - Martinez-Lopez, Joaquin
AU  - Montesinos, Pau
PY  - 2021
DO  - 10.3390/cancers13102458
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/17913
T2  - Cancers
AB  - We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with...
LA  - en
PB  - MDPI AG
KW  - NGS
KW  - acute
KW  - azacytidine
KW  - clinical trials and observations
KW  - complete remission
KW  - cytarabine
KW  - genetic risk
KW  - leukemia
KW  - leukemic cells
KW  - myelocytic
KW  - myeloid neoplasia
KW  - older adults
KW  - prognostic factors
KW  - variants
KW  - Prognosis
KW  - Tumor Burden
KW  - fludarabine
KW  - Odds Ratio
KW  - Survival Analysis
KW  - Biomarkers
KW  - Cytogenetic Analysis
KW  - Genomics
KW  - High-Throughput Nucleotide Sequencing
KW  - Gene Frequency
TI  - The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
TY  - research article
VL  - 13
ER  -